Organization · Venture Capital
Illumina Ventures
Illumina Ventures is a venture capital firm focused on early-stage companies in genomics and precision health. It leverages a strategic relationship with Illumina, Inc. to support transformative healthcare innovations.
Overview
What Illumina Ventures does
What Illumina Ventures is
Illumina Ventures is a venture capital firm focused on early-stage companies in genomics and precision health. It leverages a strategic relationship with Illumina, Inc. to support transformative healthcare innovations.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- March 7, 2026
Official channels
Find Illumina Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Illumina Ventures as a funder
Investment thesis
Illumina Ventures focuses on investing in early-stage companies that are innovating in genomics and precision health, aiming to improve human health through advancements in life sciences tools, diagnostics, therapeutics, and digital health.
Focus narrative
The firm invests primarily in early-stage companies within the genomics and precision health sectors. Key investment areas include life sciences tools, diagnostics, therapeutics, and digital health. Illumina Ventures is particularly interested in innovations related to single-cell analysis, gene editing, and agricultural biotechnology, supporting companies that are poised to make significant impacts in human health.
Value beyond capital
Illumina Ventures provides its portfolio companies with access to the Illumina ecosystem, including resources from Illumina Inc. and the Illumina Accelerator. This strategic partnership allows founders to leverage industry expertise and networks, enhancing their growth potential without the typical constraints of corporate venture capital.
Terms and economics
- Typical check
- $1,000,000–$20,000,000
- Sweet spot
- $5,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Series A · Series B
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
Portfolio context
Notable portfolio companies include: Actym Therapeutics: Focuses on systemic delivery and tumor-specific effects for cancer treatment. Alamar Biosciences: Develops precision proteomics solutions. Arbor Biotechnologies: Works on gene editing technologies. Delfi Diagnostics: Specializes in early cancer detection through liquid biopsy. Fluent BioSciences: Enhances single-cell sequencing efficiency and accessibility. Iambic Therapeutics: Develops AI-discovered therapeutics, recently raised over $100M. Redshift Bio: Measures structural changes in biomolecules. Sonothera: Develops a nonviral gene therapy platform using ultrasound guidance.
Common questions
What to know about Illumina Ventures
Upseed classifies Illumina Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 7, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.